Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 22 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Kilitch Drugs (India) Ltd

About the Company - Kilitch Drugs (India) Ltd

Kilitch Drugs(I) Ltd. is a Public Limited Listed company incorporated on 12/05/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1992PLC066718 and registration number is 066718. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 105.16 Cr. and Equity Capital is Rs. 15.58 Cr. for the Year ended 31/03/2022.
PharmaceuticalsC-301/2, M.I.D.C., TTC Industrial Area, New Mumbai Maharashtra
NamePosition Held
Mr. Mukund P MehtaManaging Director
Mr. Bhavin Mukund MehtaWhole Time Director
Mrs. Mira B MehtaWhole Time Director
Mr. Hemang EngineerIndependent Director
Mr. Venkita Subramanian RajanIndependent Director
Prof. Vasudev Krishna MurtiIndependent Director

Kilitch Drugs(I) Ltd. Share Price Update

Share PriceValue
Previous Day₹460.90

Basic Stock Data of Kilitch Drugs (India) Ltd

Market Cap 655 Cr.
Current Price 407
High / Low470/121
Stock P/E52.6
Book Value 104
Dividend Yield0.00 %
ROCE9.88 %
ROE5.40 %
Face Value 10.0

Data Source:

Kilitch Drugs (India) Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Operating Profit2.963.020.320.913.650.775.043.423.953.986.226.188.62
OPM %16.38%14.85%1.61%4.64%15.49%2.24%13.77%10.22%12.87%13.28%13.68%16.90%20.92%
Other Income0.420.371.511.050.171.310.380.970.240.691.020.560.49
Profit before tax2.702.771.171.393.001.643.582.901.552.455.124.536.78
Tax %18.52%21.30%40.17%47.48%14.00%62.80%36.03%40.00%-25.16%30.61%43.16%32.67%24.93%
Net Profit2.212.180.710.722.580.612.301.741.941.712.903.065.09
EPS in Rs1.341.430.460.761.390.721.861.341.561.522.282.162.95

Kilitch Drugs (India) Ltd Quarterly Chart

Kilitch Drugs (India) Ltd Profit & Loss

MonthMar 2010Mar 2011Mar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit232213-2-4-16705101825
OPM %16%15%12%-9%-19%-2%11%9%1%8%9%13%16%
Other Income00923213443333
Profit before tax131397-1-12-96925101219
Tax %22%20%22%70%4%5%16%55%48%27%35%31%
Net Profit101076-0-11-954146813
EPS in Rs7.757.9357.67-0.22-8.46-6.723.752.490.542.434.736.718.91
Dividend Payout %13%13%52%0%0%0%13%20%0%0%0%0%

Kilitch Drugs (India) Ltd Profit & Loss Yearly Chart

Kilitch Drugs (India) Ltd Growth

Compounded Sales Growth
10 Years:%
5 Years:22%
3 Years:38%
Compounded Profit Growth
10 Years:%
5 Years:12%
3 Years:237%
Stock Price CAGR
10 Years:38%
5 Years:17%
3 Years:72%
1 Year:216%
Return on Equity
10 Years:%
5 Years:3%
3 Years:4%
Last Year:5%

Kilitch Drugs (India) Ltd Balance Sheet

MonthMar 2010Mar 2011Mar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital13131313131314151515161616
Other Liabilities215354781115131261535141
Total Liabilities139153177127117113128144143203210220237
Fixed Assets444299423333323230656464
Other Assets726830462526353830477190104
Total Assets139153177127117113128144143203210220237

Kilitch Drugs (India) Ltd Reserves and Borrowings Chart

Kilitch Drugs (India) Ltd Cash Flow

MonthMar 2010Mar 2011Mar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 1222-29-81711044663
Cash from Investing Activity -20-2441-31-20-2-4-14-10-38-158
Cash from Financing Activity 77-9-00-0617127-1
Net Cash Flow-162-39-2-023-510-210

Kilitch Drugs (India) Ltd Financial Efficiency Indicators

MonthMar 2010Mar 2011Mar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days123975124328619614886109122132142
Inventory Days46621212411084393670352810
Days Payable4437191241541841083389525239200
Cash Conversion Cycle1251214424324196798989-367-79-48
Working Capital Days10719-11419723712410079108-1442554
ROCE %15%8%-10%-9%5%6%1%3%6%10%

Kilitch Drugs (India) Ltd Financial Efficiency Indicators Chart

Kilitch Drugs (India) Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
No. of Shareholders9,7569,2148,7409,1299,1339,2099,3809,4359,5229,5739,0029,062

Kilitch Drugs (India) Ltd Shareholding Pattern Chart

No. of Kilitch Drugs (India) Ltd Shareholders

This stock is not held by any mutual fund

Kilitch Drugs (India) Ltd ROCE Trend

Kilitch Drugs (India) Ltd EPS Trend

Kilitch Drugs (India) Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
Basic EPS (Rs.)6.714.732.370.552.61
Diluted EPS (Rs.)6.714.732.370.552.61
Cash EPS (Rs.)7.595.573.711.843.83
Book Value[Excl.RevalReserv]/Share (Rs.)96.6490.0383.5678.0580.20
Book Value[Incl.RevalReserv]/Share (Rs.)96.6490.0383.5678.0580.20
Revenue From Operations / Share (Rs.)89.5973.3144.2234.5553.72
PBDIT / Share (Rs.)13.158.525.072.807.17
PBIT / Share (Rs.)10.876.943.791.505.84
PBT / Share (Rs.)7.716.173.301.045.59
Net Profit / Share (Rs.)5.323.992.430.542.49
NP After MI And SOA / Share (Rs.)6.714.732.370.542.49
PBDIT Margin (%)14.6711.6211.478.1013.35
PBIT Margin (%)12.129.468.574.3510.86
PBT Margin (%)8.608.417.473.0110.40
Net Profit Margin (%)5.935.435.491.574.64
NP After MI And SOA Margin (%)7.486.445.351.574.64
Return on Networth / Equity (%)6.895.292.880.713.16
Return on Capital Employeed (%)11.247.694.521.927.25
Return On Assets (%)4.753.511.800.582.66
Total Debt / Equity (X)
Asset Turnover Ratio (%)0.650.480.410.380.64
Current Ratio (X)1.841.651.102.543.23
Quick Ratio (X)1.811.571.052.292.99
Inventory Turnover Ratio (X)21.1614.048.317.1014.15
Dividend Payout Ratio (NP) (%)
Dividend Payout Ratio (CP) (%)
Earning Retention Ratio (%)
Cash Earning Retention Ratio (%)
Interest Coverage Ratio (X)4.1611.0810.426.0429.06
Interest Coverage Ratio (Post Tax) (X)2.686.185.992.1811.10
Enterprise Value (Cr.)218.65272.89130.24137.43307.18
EV / Net Operating Revenue (X)1.572.391.902.583.72
EV / EBITDA (X)10.6720.5516.5731.8027.88
MarketCap / Net Operating Revenue (X)1.562.291.832.353.68
Retention Ratios (%)
Price / BV (X)1.431.880.981.062.51
Price / Net Operating Revenue (X)1.562.291.832.353.68

Kilitch Drugs (India) Ltd Profitability Ratios (%)

Kilitch Drugs (India) Ltd Liquidity Ratios

Kilitch Drugs (India) Ltd Liquidity Ratios (%)

Kilitch Drugs (India) Ltd Interest Coverage Ratios (%)

Kilitch Drugs (India) Ltd Valuation Ratios

Fair Value of Kilitch Drugs (India) Ltd Stock

Fair Value: ₹301.31

The stock is overvalued by 25.97% compared to the current price ₹407

*Investments are subject to market risks

Strength and Weakness of Kilitch Drugs (India) Ltd Stock

  1. The company has higher reserves (103.54 cr) compared to borrowings (13.69 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (86.54 cr) and profit (12.62 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 5.79 and average Dividend Yield of 9.07%.
  2. The stock has a low average ROCE of 2.92%, which may not be favorable.
  3. The stock has a high average Working Capital Days of 66.00, which may not be favorable.
  4. The stock has a high average Cash Conversion Cycle of 52.75, which may not be favorable.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Kilitch Drugs (India) Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE